nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00033137,"Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts",,Recruiting,Observational,"Kidney Neoplasms; Kidney Cancer; Pneumothorax; FLCN Protein, Human",,,National Cancer Institute (NCI),,950,2002-05-13,,United States,No,https://clinicaltrials.gov/study/NCT00033137
NCT00068003,Cell Harvest and Preparation for Surgery Branch Treatment Protocols,,Enrolling by invitation,Observational,Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small Cell Lung Cancer,Anti-CD19 CAR PBL,,National Cancer Institute (NCI),,7000,2003-09-08,,United States,No,https://clinicaltrials.gov/study/NCT00068003
NCT02178163,A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.,Not Applicable,Recruiting,Interventional,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cytology specimen collection procedure; laboratory biomarker analysis,,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),1020,2014-08-01,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT02178163
NCT02596490,Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners,Not Applicable,Recruiting,Interventional,Lung Cancer,Questionnaires; Meditation and Discussion Sessions; Cancer-Related Discussion Program,,M.D. Anderson Cancer Center,"National Cancer Institute (NCI); American Cancer Society, Inc.",300,2016-04-06,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT02596490
NCT03093116,"A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)",Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Solid Tumors; Metastatic Solid Tumors,Oral repotrectinib (TPX-0005),,"Turning Point Therapeutics, Inc.","Zai Lab (Shanghai) Co., Ltd.",500,2017-03-07,2028-02-29,Australia; Belgium; Canada; China; Denmark; France; Germany; Hong Kong; Hungary; Italy; Japan; Netherlands; Poland; Singapore; South Korea; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT03093116
NCT03586453,A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Osimertinib,,Dana-Farber Cancer Institute,AstraZeneca,30,2018-08-13,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT03586453
NCT03774758,Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening,,Recruiting,Observational,Nodule Solitary Pulmonary; Non-small Cell Lung Cancer,Guardant Health ct-DNA LUNAR assay,,"University of California, San Francisco","Northern California Institute of Research and Education; Guardant Health, Inc.",590,2017-12-17,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT03774758
NCT03948100,"Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",Not Applicable,Recruiting,Interventional,Esophageal Carcinoma; Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Educational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Yoga,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),400,2018-12-20,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03948100
NCT04093167,"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pembrolizumab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; Personal Genome Diagnostics; Mark Foundation for Cancer Research",230,2020-05-26,2027-07-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT04093167
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04155034,MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK),Phase 3,Recruiting,Interventional,Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma,Magnetic Resonance Imaging; Prophylactic Cranial Irradiation,,SWOG Cancer Research Network,National Cancer Institute (NCI),668,2020-05-04,2029-11-15,Canada; Chile; Colombia; Mexico; Saudi Arabia; South Korea; United States,No,https://clinicaltrials.gov/study/NCT04155034
NCT04253964,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,Phase 2,Recruiting,Interventional,Nonsmall Cell Lung Cancer; Performance Status,"Pembrolizumab; Carboplatin; Paclitaxel; Nab paclitaxel; Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13); QLQ-C30 Global Health/Quality of Life Questionnaire; COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes; Pemetrexed",,Wake Forest University Health Sciences,National Cancer Institute (NCI),80,2020-07-01,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT04253964
NCT04300556,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,Farletuzumab ecteribulin; Prednisone; Prednisolone; Dexamethasone; Lenvatinib,,Eisai Inc.,,182,2020-08-06,2030-08-08,France; Japan; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04300556
NCT04317534,A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153,Phase 2,Recruiting,Interventional,"NSCLC, Stage I",Pembrolizumab,,"Greg Durm, MD",Merck Sharp & Dohme LLC,244,2020-05-05,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT04317534
NCT04486833,"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",quaratusugene ozeplasmid; osimertinib; Platinum-Based Chemotherapy,,"Genprex, Inc.",,158,2021-09-03,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT04486833
NCT04551378,Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors,,Recruiting,Observational,COVID-19 Infection; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm,Quality-of-Life Assessment; Survey Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),600,2020-07-13,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT04551378
NCT04585477,Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E),Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy,,Stanford University,AstraZeneca,80,2021-04-08,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT04585477
NCT04589845,Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Phase 2,Recruiting,Interventional,Solid Tumors,Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib,,Hoffmann-La Roche,,920,2021-01-18,2032-09-25,Australia; Belgium; Brazil; Canada; China; Denmark; France; Germany; Hong Kong; Israel; Italy; Japan; New Zealand; Poland; Portugal; Puerto Rico; Singapore; South Africa; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04589845
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04762199,"A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Flt3/MerTK Inhibitor MRX-2843; Osimertinib,,Emory University,National Cancer Institute (NCI),69,2021-02-24,2026-12-27,United States,No,https://clinicaltrials.gov/study/NCT04762199
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05168566,"A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Sutetinib Maleate Capsule,,Teligene US,,99,2022-09-01,2026-06-05,China; United States,No,https://clinicaltrials.gov/study/NCT05168566
NCT05261399,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",Phase 3,Recruiting,Interventional,Carcinoma; Non-Small-Cell Lung,Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin,,AstraZeneca,,324,2022-08-03,2026-12-17,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Netherlands; Philippines; Poland; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05261399
NCT05332925,Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN),,Recruiting,Observational,Lung Cancer; NSCLC; NSCLC Stage IV,Standard of care immune checkpoint inhbitors,,"Jun Zhang, MD, PhD",Nilogen Oncosystems,25,2022-07-21,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05332925
NCT05384626,A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1),Phase 1/Phase 2,Recruiting,Interventional,Locally Advanced Solid Tumor; Metastatic Solid Tumor,Neladalkib (NVL-655),,Nuvalent Inc.,,840,2022-06-09,2028-01-05,Australia; Belgium; Canada; France; Germany; Italy; Japan; Netherlands; Singapore; South Korea; Spain; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05384626
NCT05419375,Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors,Phase 2,Recruiting,Interventional,Solid Tumors,Screening platform,,Hoffmann-La Roche,,15000,2022-07-22,2032-12-22,Australia; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; France; Germany; Hong Kong; India; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Serbia; Singapore; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05419375
NCT05500092,"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Nivolumab; (8gy x 3); Platinum Doublet,,Montefiore Medical Center,Bristol-Myers Squibb,52,2023-01-25,2025-07-05,United States,No,https://clinicaltrials.gov/study/NCT05500092
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05544019,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies",Phase 1,Recruiting,Interventional,"Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma",SGR-1505,,"Schrödinger, Inc.",,52,2023-04-10,2026-03-05,France; Italy; Moldova; Poland; Romania; Spain; Ukraine; United States,No,https://clinicaltrials.gov/study/NCT05544019
NCT05578326,Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Lung Cancer; Small-cell Lung Cancer,Trilaciclib; Lurbinectedin,,UNC Lineberger Comprehensive Cancer Center,"G1 Therapeutics, Inc.",30,2022-10-12,2027-12-25,United States,No,https://clinicaltrials.gov/study/NCT05578326
NCT05642572,"A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",Phase 2,Recruiting,Interventional,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Capmatinib; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Ramucirumab,,SWOG Cancer Research Network,National Cancer Institute (NCI),66,2023-05-05,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT05642572
NCT05669846,Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Healthy Donor Fecal Microbiota Transplant (hdFMT); Pembrolizumab,,Diwakar Davar,Gateway for Cancer Research,26,2025-01-08,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT05669846
NCT05715229,A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed,,Hackensack Meridian Health,MedSIR,108,2023-09-29,2026-04-28,United States,No,https://clinicaltrials.gov/study/NCT05715229
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05845671,"A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",Phase 1/Phase 2,Recruiting,Interventional,Lung Cancer; Non Small Cell Lung Cancer,Amivantamab 1050mg; Amivantamab 1400mg; Amivantamab (to be determined); Amivantamab (to be determined),,"University of Colorado, Denver","Janssen Research & Development, LLC",12,2023-07-17,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT05845671
NCT05876923,The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients,Not Applicable,Recruiting,Interventional,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Indolent Non-hodgkin Lymphoma,Biospecimen Collection; Cardiopulmonary Exercise Testing; Dual X-ray Absorptiometry; Electronic Health Record Review; Exercise Intervention; Physical Examination; Questionnaire Administration; Spirometry; Physical Performance Testing; Best Practice,,Mayo Clinic,,70,2023-06-12,2028-04-05,United States,No,https://clinicaltrials.gov/study/NCT05876923
NCT05892068,Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Tucatinib,,Memorial Sloan Kettering Cancer Center,Pfizer; Seagen Inc.,28,2023-05-09,2028-05-09,United States,No,https://clinicaltrials.gov/study/NCT05892068
NCT06007937,A Phase 1/2 Study of Combination Lorlatinib and Ramucirumab in Patients With Advanced ALK-rearranged Lung Cancers,Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Metastatic; Recurrent,Lorlatinib; Ramucirumab,,Memorial Sloan Kettering Cancer Center,Eli Lilly and Company,56,2023-08-17,2028-08-17,United States,No,https://clinicaltrials.gov/study/NCT06007937
NCT06074588,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan; Docetaxel; Pemetrexed,,Merck Sharp & Dohme LLC,,556,2023-11-12,2030-03-11,Australia; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Mexico; Philippines; Poland; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06074588
NCT06117774,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy",Phase 3,Recruiting,Interventional,Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer,Tarlatamab; Placebo,,Amgen,,400,2024-02-20,2030-05-29,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; China; Colombia; France; Germany; Greece; Hong Kong; Italy; Japan; Mexico; Poland; Portugal; Romania; Singapore; South Korea; Spain; Sweden; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06117774
NCT06124118,A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC,Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer,carboplatin chemotherapy; NovoTTF-200T (TTFields) System; Durvalumab,,University of Utah,,30,2024-04-04,2026-11-15,United States,No,https://clinicaltrials.gov/study/NCT06124118
NCT06225804,"A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,ABSK112,,"Abbisko Therapeutics Co, Ltd",,164,2024-02-22,2028-03-05,China; United States,No,https://clinicaltrials.gov/study/NCT06225804
NCT06252129,Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens,Not Applicable,Recruiting,Interventional,Lung Cancer; Lymph Node Metastasis; Pathologic Processes,Subjects undergoing a lung specimen lymph node dissection; Control group,,Brigham and Women's Hospital,,160,2024-07-26,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06252129
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06312137,A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery,Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication,,Merck Sharp & Dohme LLC,,780,2024-04-03,2034-10-23,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Romania; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06312137
NCT06385262,"Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Alirocumab; Cemiplimab; Chemotherapy,,Duke University,Regeneron Pharmaceuticals,126,2025-03-17,2029-10-30,United States,No,https://clinicaltrials.gov/study/NCT06385262
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06401330,Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT),Phase 3,Recruiting,Interventional,Stage I Mixed Cell Type Kidney Wilms Tumor; Stage II Mixed Cell Type Kidney Wilms Tumor; Stage III Mixed Cell Type Kidney Wilms Tumor; Stage IV Mixed Cell Type Kidney Wilms Tumor,Bone Scan; Carboplatin; Computed Tomography; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Irinotecan; Magnetic Resonance Imaging; Nephrectomy; Patient Observation; Positron Emission Tomography; Ultrasound Imaging; Vincristine; X-Ray Imaging,,Children's Oncology Group,,1656,2025-04-15,2031-02-13,Canada; United States,No,https://clinicaltrials.gov/study/NCT06401330
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab; sac-TMT; Carboplatin; Paclitaxel; Nab-paclitaxel,,Merck Sharp & Dohme LLC,,851,2024-06-10,2031-02-12,Argentina; Austria; Brazil; Canada; Chile; China; Colombia; Czechia; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Peru; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06422143
NCT06545331,A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer; NSCLC (Non-small Cell Lung Cancer); Hormone-receptor-positive Breast Cancer; Triple Negative Breast Cancer (TNBC),XB010; Pembrolizumab,,Exelixis,,396,2024-08-06,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT06545331
NCT06555744,"A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumors,ZW191,,Zymeworks BC Inc.,,145,2024-10-30,2027-01-05,Australia; Japan; Singapore; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06555744
NCT06561386,"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin,,Bristol-Myers Squibb,,1000,2024-10-07,2032-08-04,Argentina; Australia; Austria; Belgium; Brazil; Chile; China; Colombia; Denmark; France; Germany; India; Ireland; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Romania; Saudi Arabia; South Africa; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06561386
NCT06566443,Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Honokiol,,The Methodist Hospital Research Institute,,15,2024-11-08,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT06566443
NCT06593522,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,MTAP-deleted NSCLC,AMG 193,,Amgen,,200,2024-12-26,2030-11-29,Australia; Brazil; Canada; China; Czechia; Hong Kong; Japan; Latvia; Netherlands; Portugal; Singapore; South Korea; Switzerland; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06593522
NCT06671613,Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer,Not Applicable,Recruiting,Interventional,Stage IV NSCLC; NSCLC; Immunotherapy; Fasting Mimicking Diet,FMD; Regular Diet Plus FMD,,VA Office of Research and Development,Indiana University; US Department of Veterans Affairs Cooperative Studies Program; L-Nutra Inc,66,2025-10-27,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT06671613
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06712745,Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung,Early Phase 1,Recruiting,Interventional,"Cancer, Lung; Metastasis",Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR),,University of Texas Southwestern Medical Center,Elekta Limited,30,2025-09-19,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06712745
NCT06814496,RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3,Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer; Merkel Cell Carcinoma,Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy,,University of Arizona,Amgen,30,2025-09-08,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT06814496
NCT06834373,Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL),Phase 2,Recruiting,Interventional,"Large B-Cell Lymphoma With IRF4 Rearrangement; Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma; Recurrent ALK-Positive Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Intravascular Large B-Cell Lymphoma; Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Recurrent Primary Mediastinal Large B-Cell Lymphoma; Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory Aggressive B-Cell Non-Hodgkin Lymphoma; Refractory ALK-Positive Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Intravascular Large B-Cell Lymphoma; Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Refractory Primary Mediastinal Large B-Cell Lymphoma; Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma",Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Chimeric Antigen Receptor T-Cell Therapy; Computed Tomography; Golcadomide; Leukapheresis; Positron Emission Tomography; Rituximab,,Mayo Clinic,,41,2025-04-02,2027-03-03,United States,No,https://clinicaltrials.gov/study/NCT06834373
NCT06973564,"A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,JAB-23E73; JAB-23E73; JAB-23E73,,"Jacobio Pharmaceuticals Co., Ltd.",,294,2025-05-29,2028-02-05,United States,No,https://clinicaltrials.gov/study/NCT06973564
NCT07125183,A Phase II Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma of Soft Tissue,Phase 2,Recruiting,Interventional,Sarcoma,Doxorubicin,,"University of Colorado, Denver",Cancer League of Colorado,20,2025-12-05,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT07125183
NCT07132918,The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers,Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer (Stage III); Esophageal Cancer Stage I-III; Esophagogastric Cancer Stage I-III; Thymoma and Thymic Carcinoma Stage II-III; Other Cancers in the Thoracic Region,MRgART; LINAC,,"University of Wisconsin, Madison","National Heart, Lung, and Blood Institute (NHLBI)",60,2025-10-08,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT07132918
NCT07140016,A Phase 1b Study of Gilteritinib in Participants With Locally Advanced or Metastatic NSCLC With ALK Rearrangement After Prior Treatment With an ALK Inhibitor,Phase 1,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC); Anaplastic Lymphoma Kinase (ALK) Positive,gilteritinib,,"Astellas Pharma Global Development, Inc.",,40,2025-09-22,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT07140016
NCT07155187,Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI,Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Telisotuzumab Adizutecan; Standard of Care,,AbbVie,,430,2025-12-10,2030-09-05,Australia; Israel; Japan; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT07155187
